Charles River Labs stock analysis
Charles River Labs (RV6) Stock Price & Analysis
RV6 Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 13.79B
- Enterprise Value
- CHF 16.90B
- Total Cash (Recent Filing)
- CHF 200.38M
- Total Debt (Recent Filing)
- CHF 2.85B
- Price to Earnings (P/E)
- 336.0
- Beta
- 1.39
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- 2.74
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
DSA Demand And Backlog Strength
Strong DSA bookings, a book-to-bill above one, and a growing backlog provide durable visibility into future service revenue. Continued demand for regulated safety assessment supports utilization, customer retention, and operating leverage across the core business.
Resilient Cash Generation
Meaningful operating and free cash flow gives Charles River internal funding capacity during a weaker earnings cycle. This supports investment in growth initiatives, debt reduction, and client capabilities while reducing reliance on external capital for ongoing operations.
Broader Drug-development Capabilities
Adding Frontage’s bioanalysis and DMPK operations should broaden Charles River’s scientific offering and deepen its role across development stages. Greater service continuity can strengthen client relationships, increase wallet share, and reinforce the company’s position as an integrated partner.
Bears Say
Material Earnings Deterioration
The sharp revenue contraction and compressed operating profitability indicate that recent earnings power remains materially below prior levels. Until volume, cost structure, and operating margins recover sustainably, weaker profits could constrain reinvestment and reduce resilience.
RMS And End-market Weakness
Weak RMS volumes and continued pressure from academic, government, and early-stage biotech customers create a persistent drag on the portfolio. These demand issues can limit growth in research models and delay a broad recovery even as larger biopharma spending improves.
Limited Pricing Benefit
Delayed pricing realization means Charles River may need to absorb cost pressure without near-term revenue support from improved pricing. Because new proposals must work through the backlog, margin expansion depends more heavily on volume and efficiency initiatives.
Charles River Labs News
RV6 FAQ
What is Charles River Labs’s market cap?
When is Charles River Labs’s upcoming earnings report date?
How were Charles River Labs’s earnings last quarter?
Is Charles River Labs overvalued?
Does Charles River Labs pay dividends?
What is Charles River Labs’s EPS estimate?
How many shares outstanding does Charles River Labs have?
What happened to Charles River Labs’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Charles River Labs?
What is the TipRanks Smart Score and how is it calculated?
Charles River Labs Stock Smart Score
Company Description
Charles River Labs
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Birgit Girshick
- Employees
- 19,000
- Website
- www.criver.com
- Address
- 251 Ballardvale Street, Wilmington, MA, 01887, US
Charles River Labs (RV6) Earnings & Revenues
RV6 Company Deck
RV6 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. The company reported stronger-than-expected revenue, earnings, margins, bookings, backlog, and cash flow; raised full-year revenue and EPS guidance; and described improving biopharmaceutical demand, manufacturing momentum, strategic client expansion, and progress in modernization and scientific initiatives. The main challenges were the RMS decline, continued academic and government funding pressure, limited current pricing power, higher interest expense, and the remaining recovery in early-stage biotech activity.
View all CH:RV6 earnings summariesRV6 Net sales Breakdown
- 21.07% RMS
- 59.84% DSA
- 19.09% Manufacturing
